Strides Shasun gets USFDA nod for generic Ibuprofen capsules

Answer: Nostrum (File imagDivis Laboratories share price performance in FY18: Up 75 percent | FY19: Up 56 percent | FY20: Up 17 percent.e)

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Drug firm Strides Shasun today said it has received approval from the US health regulator for generic Ibuprofen capsules, 200 mg, used for relieving pain.

The company's wholly-owned subsidiary Strides Pharma Global has received approval for Ibuprofen capsules in the strength of 200 mg from the United States Food & Drug Administration (USFDA), Strides Shasun said in a statement.

The company's product is a generic version of Pfizer Inc's Advil Liqui-Gels 200 mg, it added.

According to IRi data, the US OTC market for Ibuprofen capsules is approximately USD 300 million, Strides Shasun said.

"With a focus to secure its API supply chain for the product, the company under prior approval supplements filing will apply for a source change to Solara Active Pharma Sciences, a group company having a leading API franchise," it added.

The product will be commercialised in Q4 of FY19 post completion of API source change process, Strides Shasun said.

The product will be manufactured at the company's oral dosage facility in Bangalore, it added. The company has 74 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 45 ANDAs have been approved as of date and 29 are pending approval, Strides Shasun said.

Shares of Strides Shasun were today trading at Rs 680.95 per scrip in the afternoon trade on BSE, up 1.32 percent from its previous close.